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S U M M A R Y
Objectives: Community-acquired Klebsiella pneumoniae has emerged as a major cause of liver abscess in
Asia. Using a standardized protocol, we conducted a prospective cohort study of all cases of K.
pneumoniae liver abscess treated from 2005 to 2011 at two outpatient parenteral antimicrobial therapy
(OPAT) centers in Singapore, to assess the safety and efﬁcacy of treatment.
Methods: We included all OPAT eligible patients with radiologically conﬁrmed (computed tomography
or ultrasound) liver abscesses and K. pneumoniae-positive microbiological cultures obtained from
abscess ﬂuid and/or blood at two university teaching hospitals. The endpoints investigated were cure,
clinical response, readmission, and mortality.
Results: All 109 patients enrolled in the study successfully completed treatment in OPAT. Nine patients
required a short-term readmission due to clinical deterioration. There were no deaths or relapses at 30
days post cessation of antibiotics. Abscess size greater than 5 cm was associated with a delayed clinical
response (odds ratio 5.34, 95% conﬁdence interval 1.25–22.91, p = 0.02).
Conclusion: The management of K. pneumoniae liver abscesses via OPAT using a standardized protocol is
a safe and effective alternative to inpatient intravenous antibiotics.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Pyogenic liver abscess is a condition with mortality rates
ranging from 11% to 31%.1 It may be caused by a number of
organisms including Escherichia coli, Klebsiella pneumoniae, Strep-
tococcus anginosus, and anaerobes such as Bacteroides species.2 In
the last 20 years, community-acquired pyogenic liver abscess
caused by K. pneumoniae has emerged in Taiwan and other Asian
countries as a unique entity. In particular, the hypermucoid K1 and
K2 capsular serotypes have been found to be associated with
metastatic infections and more severe disease.3 In Singapore, K.
pneumoniae is the most common organism isolated in patients
with pyogenic liver abscess.4
The management of liver abscesses involves a combination of
antimicrobials to which the offending organism is susceptible and
drainage where indicated. Radiologically guided percutaneous
aspiration has in many cases replaced surgical drainage, resulting
in shorter hospital stays and fewer complications.5* Corresponding author. Tel.: +65 91774393; fax: +65 67771613.
E-mail address: douglas_sg_chan@nuhs.edu.sg (Douglas S.G. Chan).
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involves 2 to 3 weeks of parenteral administration followed by oral
antibiotics to complete a total 4- to 6-week course.2,6 The availability
of outpatient parenteral antimicrobial therapy (OPAT) services
potentially allows patients to have their parenteral antibiotics
administered out of the hospital for at least part of the course.
We conducted a prospective cohort study examining the safety
and efﬁcacy as well as risk factors for a poor clinical response in K.
pneumoniae liver abscess (KLA) cases treated via OPAT in
Singapore.
2. Materials and methods
2.1. Study sites
The National University Hospital (NUH) and Tan Tock Seng
Hospital (TTSH) are university teaching hospitals with OPAT
centers catering to patients requiring intravenous antibiotic
therapy. The two centers provide the majority of OPAT services
in Singapore, enrolling an average of 500 patients per year (794 and
706 patients, respectively, in the last 3 years). Consecutive cases of
KLA treated via OPAT at NUH and TTSH from January 2005 to July
2011 were enrolled and monitored prospectively.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Patient demographics (n = 109)
Variable Finding
Male sex 72
Age, years, mean  SD (range) 57  13 (26–83)
Co-morbidities, n (%)
Diabetes 49 (45%)
Hypertension 48 (44%)
Renal impairment 6 (6%)
Ischemic heart disease 6 (6%)
Hyperlipidemia 30 (28%)
Underlying malignancy 13 (12%)
SD, standard deviation.
Table 2
Patient outcomes
Variable Mean  SD (range)
Length of hospital stay, days 15  10 (3–84)
Length of OPAT administered antibiotics 16  9 (2–54)
Delayed clinical response at 4 weeks, n 29
Readmission from OPAT during parenteral therapy, n 9
Total duration of IV therapy, days 32  13 (11–98)
Duration of subsequent oral therapy, days 42  26 (7–140)
SD, standard deviation; OPAT, outpatient parenteral antimicrobial therapy; IV,
intravenous.
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Patients were enrolled into the OPAT service after being
assessed by an infectious diseases physician and an OPAT specialist
nurse. To be eligible, patients had to have an infection requiring
intravenous antibiotics that were appropriate for OPAT adminis-
tration, venous access, and social circumstances deemed safe. Our
inclusion criteria were OPAT eligible patients with radiologically
conﬁrmed (computed tomography or ultrasound) liver abscesses
and K. pneumoniae-positive microbiological cultures obtained from
abscess ﬂuid and/or blood.
Patients with non-K. pneumoniae liver abscesses were excluded
from the analysis. The choice of antibiotic was based on the
susceptibility proﬁles reported by the microbiology laboratory of
each hospital.
2.3. Study procedures
Patients were managed using a standardized protocol: (1) daily
clinical nursing review to assess for any adverse events; (2) weekly
physician review of clinical features and laboratory parameters
including full blood count, liver function tests, electrolytes,
creatinine, and C-reactive protein (CRP); (3) repeat imaging of
liver abscesses with either ultrasound or computed tomography
prior to antibiotic cessation or conversion to oral therapy.
2.4. Microbiology
The identiﬁcation and susceptibility testing of K. pneumoniae
isolates were performed using the VITEK 2 system (bioMe´rieux) at
NUH during the entire duration of the study. At TTSH, organism
identiﬁcation was performed using a mix of MicrobactTM 12A
(Oxoid, UK), VITEK 2 system (bioMe´rieux), and the Bruker Biotyper
(version 2.0) matrix-assisted laser desorption/ionization time-of-
ﬂight (MALDI-TOF) mass spectrometry system; susceptibility
testing was performed using the VITEK 2 system (bioMe´rieux)
and Kirby–Bauer method. At NUH, interpretation of susceptibility
was based on the Clinical and Laboratory Standards Institute (CLSI)
breakpoints from 2005 to 2009, after which the European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
breakpoints were used. At TTSH, CLSI breakpoints were used
during the entire duration of the study.
2.5. Study outcomes
Our endpoints were cure, clinical response, readmission, and
mortality. Cure was deﬁned as the absence of symptoms,
normalization of CRP (<10 mg/l), radiologic resolution, and no
signs of relapse at 30 days post cessation of antibiotics. Clinical
response was deﬁned as resolution of symptoms with normali-
zation of CRP to <10 mg/l at 4 weeks of therapy. Readmission
was deﬁned as an admission from OPAT to hospital while still
receiving antimicrobial therapy for KLA. Mortality was deﬁned
as death during OPAT therapy or within 30 days of cessation of
antibiotics.
2.6. Data collection
The two OPAT services shared a common prospective OPAT
database to record patient demographics (age, gender), microbiol-
ogy and site of infection, antibiotic selection and duration, type of
intravenous access, and mode of administration. Medical and
laboratory records provided additional data on co-morbidities,
antibiotic susceptibility, radiological ﬁndings (size of abscess and
presence of loculations), laboratory results (white blood cell
count, liver function tests, CRP), and any intervention includingpercutaneous or surgical drainage. Other data collected included
length of hospital stay before discharge to OPAT and length of
OPAT.
2.7. Statistical analysis
All statistical analyses were performed using SPSS 18.0 (PASW).
Associations of the categorical variables with readmission and
clinical response were assessed using the Chi-square/Fisher’s exact
test and logistic regression for multivariate analysis. Odds ratios
(OR) and their 95% conﬁdence intervals (CI) were presented, with
statistical signiﬁcance set at p < 0.05.
3. Results
Of 205 patients with pyogenic liver abscess treated in the two
OPAT centers between January 2005 and July 2011, 109 had KLA and
were included in the study (Table 1). Seventy-two (66%) were male
and the mean age was 57 years (standard deviation (SD) 13). K.
pneumoniae was identiﬁed from blood cultures in 71 (65%) patients
and liver abscess ﬂuid only in 38 (35%) patients. Of the blood culture-
positive cases, 32 had K. pneumoniae also isolated in the liver abscess.
Two of the patients who underwent aspiration/surgical drainage
were culture-negative despite being bacteremic. The size of the liver
abscesses was greater than 5 cm in 71 patients (65%). The mean
length of hospital stay was 15 days (SD 10), while the mean length of
OPAT management was 16 days (SD 9) (Table 2).
Surgical drainage was undertaken in seven patients and
radiologically guided drainage in 65 patients. Drainage was
deemed inappropriate in 37 patients (34%) due to the radiologic
appearance of the abscess.
Of 71 patients with abscesses greater than 5 cm in diameter, 60
(85%) were treated with drainage and antibiotics while the
remainder received antibiotics alone. Twenty-six of the 38 patients
(68%) with abscesses less than 5 cm in diameter had antibiotic
treatment alone. Antibiotics were selected based on the suscepti-
bility patterns of K. pneumoniae reported by the microbiology
laboratories. In no instance was antibiotic use discordant with the
antimicrobial susceptibility of the organism. Ceftriaxone was most
commonly used (71 cases, 65%), while cefazolin was given to 24
Table 3
Variables associated with a poor outcome
Variables Lack of clinical response at 4 weeks Readmission
OR 95% CI p-Value OR 95% CI p-Value
Age >60 years 1.46 0.52–4.09 0.47 3.05 0.34–27.57 0.32
Male sex 0.72 0.26–1.98 0.52 0.29 0.03–2.66 0.28
Diabetic 1.13 0.42–3.04 0.81 0.55 0.05–6.22 0.63
Bacteremia 1.16 0.40–3.35 0.78 9.83 0.65–149.0 0.10
Abscess size >5 cm 5.34 1.25–22.91 0.02 2.40 0.16–37.02 0.53
Loculation 0.52 0.14–1.87 0.31 N/A N/A N/A
Percutaneous drain 0.82 0.25–2.71 0.74 10.0 0.51–195.11 0.13
OR, odds ratio; CI, conﬁdence interval; N/A, not applicable.
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one. Comparing cefazolin and ceftriaxone treatment, there was no
difference in clinical response or readmission from OPAT to
hospital.
Eighty patients achieved a clinical response at 4 weeks. A
delayed clinical response (i.e., patient still symptomatic and/or CRP
>10 mg/l at 4 weeks of therapy) was noted in 29 patients (27%)
(Table 2). This was associated with abscess size greater than 5 cm
in diameter (Table 3) (OR 5.34, 95% CI 1.25–22.91; p = 0.02). Nine
patients were readmitted from OPAT, three for surgical drainage
after failing initial percutaneous drainage of their liver abscesses,
ﬁve for worsening of underlying non-infectious co-morbidities,
and one for an infectious condition unrelated to the KLA. All
patients in the study achieved cure, with no deaths or relapses at
30 days post cessation of antibiotics, including the nine read-
missions who subsequently completed OPAT.
4. Discussion
Except for a delayed clinical response at 4 weeks in patients
with liver abscesses greater than 5 cm in size, our study found no
differences in the outcomes of patients with KLA managed in OPAT
across a range of host, disease, and treatment factors (Table 3).
The age of patients with K. pneumoniae liver abscesses in
previous studies has ranged from 55 to 60 years.7 The mean age of
our cohort of patients was 57 years. Older age may or may not be
associated with increased mortality.8,9 We found no differences in
clinical response or readmission rates in patients older than 60
years.
Diabetes mellitus is a known risk factor for the development of
K. pneumoniae liver abscess and was overrepresented in our cohort
(45%). We found that the presence of diabetes mellitus was not
associated with a poor clinical response or increased risk of
readmission. This supports the ﬁndings of Lee et al., who reported
no association between diabetes mellitus and severe disease or
death.10 Diabetes has, however, been identiﬁed as a risk factor for
metastatic complications.11
We did not ﬁnd any differences in clinical response or
readmission from OPAT to hospital between patients on cefazolin
and those on ceftriaxone. In their study comparing the use of
cefazolin versus an extended-spectrum cephalosporin for treating
KLA, Cheng et al. found a signiﬁcantly higher complication rate in
patients treated with cefazolin. They hypothesized that this could
be due to inoculum-dependent inactivation of the antibiotic by
chromosomally mediated SHV-1 beta-lactamases, which are
expressed by all strains of K. pneumoniae.6 However in their
retrospective analysis of 110 episodes of KLAs, Lee et al. concluded
that the use of ﬁrst-generation cephalosporins and percutaneous
drainage was associated with low rates of mortality, metastatic
infection, and complications, and that these rates were comparable
to those reported for third-generation cephalosporins.10Liver abscesses greater than 5 cm in diameter had a higher rate
of treatment failure if treated medically alone.12 Large abscesses
have been found to be a poor prognostic indicator for mortality.13
In our cohort of patients, 85% of liver abscesses that were greater
than 5 cm in diameter were subject to either radiologically guided
percutaneous aspiration (n = 53) or open/laparoscopic surgical
drainage (n = 7). Patients with abscesses larger than 5 cm in
diameter had a delay in clinical response. However this was not
associated with an increased risk of readmission or mortality.
None of the 37 patients who were treated medically alone
required readmission or incurred any other adverse outcome post
discharge. Furthermore they trended towards shorter total
treatment courses (mean duration of 63  29 days versus
72  31 days in those with drainage). The fact that up to two-thirds
of these patients had smaller abscesses that could be treated
successfully with medical therapy alone may account for this. The
presence of loculations within the abscess was not associated with a
worse outcome, reinforcing the ﬁndings of previous studies that have
shown percutaneous drainage to be a safe and effective procedure in
treating pyogenic liver abscess regardless of abscess complexity and/
or multiplicity.14
There were nine patients readmitted from OPAT. Three were
readmitted for surgical drainage after failing initial percutaneous
drainage and all of them had abscesses greater than 5 cm in
diameter. In a series of 80 patients, Tan et al. found that for liver
abscesses larger than 5 cm, surgical drainage resulted in better
outcomes than percutaneous drainage in terms of treatment
success and the necessity for secondary procedures.15
K. pneumoniae liver abscesses can be managed effectively and
safely via OPAT in situations where guidelines are in place for
reducing the clinical risk by draining pus when abscesses are large
(i.e., greater than 5 cm), administering appropriate antibiotics
based on the susceptibility proﬁle of the organism, and monitoring
patients clinically using a standardized protocol.
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